Verdict Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Triple combo: calming Alzheimer’s agitation with AI, wearables and a novel drug

BioXcel Therapeutics is developing an acute agitation drug, BXCL501, for Alzheimer’s disease. To improve management and prevention of agitation, the company is leveraging an existing wearable device and developing AI algorithms to predict and prevent aggressive agitation. Allie Nawrat explores this novel, triple combination initiative to prevent and treat symptoms of Alzheimer’s.


Go Top